RIGEL PHARMACEUTICALS, INC. Debt Securities, Available-for-sale, Unrealized Gain (Loss)
RIGEL PHARMACEUTICALS, INC. (RIGL) reported Debt Securities, Available-for-sale, Unrealized Gain (Loss) of $107.00 thousand for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-04.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss · last filed 2025-11-04
- RIGEL PHARMACEUTICALS, INC. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2025-09-30 was $88.00K.
- RIGEL PHARMACEUTICALS, INC. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2025-06-30 was $14.00K.
- RIGEL PHARMACEUTICALS, INC. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2025-03-31 was $5.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2025-09-30 | $88.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $102.00K derived: sum of 2 quarters · filed 2025-11-04 | $107.00K 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $14.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $19.00K 10-Q · filed 2025-08-05 | ||
| 2025-03-31 | $5.00K 10-Q · filed 2025-05-06 | |||
| 2024-12-31 | $10.00K 10-Q · filed 2025-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |